Home » Public Policy

Regulatory Affairs

The Economic Contributions of the Biotechnology Industry

This report presents the estimates of the significant financial contributions of the biotechnology industry to the U.S. economy and to revenues collected by the federal, state and local governments.

Hindering Progress: Gene Patent Limits Could Impede Innovation

A new federal recommendation could hinder innovations from biotechnology R&D by limiting gene patents and licenses.

Bright Spot for Biotech: Golden State Leads in Jobs
Rare Diseases: Can We Speed Treatments?
BioBytes: Genetically Engineered Animals

Disease resistant animals, environmentally friendly livestock, pharmaceuticals produced by goats - are these really possible?

Regulatory Relief: House Passes SOX Relief Bill

In 2010, a lessening of the regulatory burden on biotech startups looks promising.

BioBytes: What are biosimilars?

Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. 

Indirect Land Use Change, Low Carbon Fuel Standards, & Cap and Trade

Biofuels have the potential to play a critical role in addressing climate change

Tricia Brooks and James Trussell Discuss Stem Cell Research and Parkinson's Cures

BIO supports all avenues of research to investigate therapies for debilitating diseases such as Parkinson's.

The Importance of President Obama's Executive Order on Embryonic Stem Cells

In this interview, BIO President and CEO Jim Greenwood explains the promise of stem cell research and why it is an important first step in bringing new therapies to patients.

Regulatory Framework for GE Animals and their Products

BIO and its members engaged in animal biotechnology support a strong federal regulatory system to oversee development and approval of all genetically engineered (GE) animals and the products derived from them.

Guide to Biotechnology 2008

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

2007-2008 BIO Milestones

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

Milestones in 2006-2007

What happens in Washington influences biotechnology progress every bit as much as what happens on Wall Street or in the lab.

The Measure of a Great Industry is Who's Listening

In June 2003, the Biotechnology Industry Organization (BIO) brought its annual convention to Washington, D.C., setting the stage for an unprecedented exchange of views and expectations between biotechnology leaders and our nation’s top public officials.

Letters, Testimony & Comments

Cell and Gene Therapy: BIO Comments on Preclinical Assessment of Investigational Cellular and Gene Therapy Products
February 27 2013
    Dear Sir/Madam:    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration...
Electronic Submissions: BIO Comments on Providing Submissions in Electronic Format
February 19 2013
    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the...
SMU: BIO Statement on Creating an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need
February 4 2013
  The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to provide...
BIO Principles on Patient Safety in the Substitution of Biologic Products
January 24 2013
Biologics are complex medicines manufactured from living organisms. Unlike traditional “small molecule” drugs, biologics are...
Statement in Opposition to North Dakota S. 2066
January 24 2013
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO represents more than 1,...
More Letters, Testimony & Comments →

Press Releases

Ken Lisaius Named BIO's Vice President of Communications
January 23 2013
Washington, D.C. (January 23, 2013) –  The Biotechnology Industry Organization (BIO) announced that Ken...
BIO Strongly Opposes RFS Waiver Requests in Comments to EPA
October 9 2012
Any waiver of the RFS would have little to no effect on corn prices, but would certainly harm biofuel producers and...
Release of FDA Guidance for Biosimilars Pathway Marks Important Step Forward, Says BIO
February 9 2012
Patient Safety Must Remain Top Priority Washington, D.C. (February 9, 2012) — Biotechnology Industry...
BIO Comments on New Initiatives to Grow Nation’s Bioeconomy
September 16 2011
Washington, D.C. (September 16, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim...
Synthetic Biology’s Potential for Commercial Innovation Should Be Supported, BIO Argues
September 1 2011
WASHINGTON, D.C.(Sept. 1, 2011) – Research and development in synthetic biology is an evolution of...
More Press Releases →